Earliest radiological progression in glioblastoma by multidisciplinary consensus review

Journal of Neuro-oncology
Roelant S EijgelaarMarnix G Witte

Abstract

Detection of glioblastoma progression is important for clinical decision-making on cessation or initiation of therapy, for enrollment in clinical trials, and for response measurement in time and location. The RANO-criteria are considered standard for the timing of progression. To evaluate local treatment, we aim to find the most accurate progression location. We determined the differences in progression free survival (PFS) and in tumor volumes at progression (Vprog) by three definitions of progression. In a consecutive cohort of 73 patients with newly-diagnosed glioblastoma between 1/1/2012 and 31/12/2013, progression was established according to three definitions. We determined (1) earliest radiological progression (ERP) by retrospective multidisciplinary consensus review using all available imaging and follow-up, (2) clinical practice progression (CPP) from multidisciplinary tumor board conclusions, and (3) progression by the RANO-criteria. ERP was established in 63 (86%), CPP in 64 (88%), RANO progression in 42 (58%). Of the 63 patients who had died, 37 (59%) did with prior RANO-progression, compared to 57 (90%) for both ERP and CPP. The median overall survival was 15.3 months. The median PFS was 8.8 months for ERP, 9.5 mont...Continue Reading

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Oct 11, 2002·Statistics in Medicine·John O'Quigley, Janez Stare
Jul 10, 2007·Acta Neuropathologica·David N LouisPaul Kleihues
May 3, 2008·The Lancet Oncology·Dieta BrandsmaMartin J van den Bent
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Apr 10, 2014·Journal of Neuro-oncology·Timothy Charles RykenUNKNOWN AANS/CNS Joint Guidelines Committee
Nov 21, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Norbert GalldiksKarl-Josef Langen
Sep 14, 2015·Neuro-oncology·Mark S ShiroishiWhitney B Pope
Oct 23, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raymond Y HuangPatrick Y Wen
Nov 8, 2015·The Lancet Oncology·Hideho OkadaDavid A Reardon
Dec 18, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sied KebirUlrich Herrlinger
Feb 3, 2016·Critical Reviews in Oncology/hematology·Katharina SeystahlMichael Weller
Jul 28, 2016·Current Treatment Options in Oncology·Alicia TosoniAlba A Brandes
Sep 9, 2017·AJNR. American Journal of Neuroradiology·N VerburgP C De Witt Hamer
Sep 29, 2017·Journal of Neuro-oncology·Charlotte KellyMatt Williams
Dec 1, 2015·Neuro-oncology Practice·Susan M ChangMartin J van den Bent

❮ Previous
Next ❯

Citations

Feb 16, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicole L GoerigRainer Fietkau
May 4, 2021·Radiology. Artificial Intelligence·Roelant S EijgelaarMarnix G Witte
Oct 12, 2021·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Danielle L WeilerJason R Powell

❮ Previous
Next ❯

Methods Mentioned

BETA
imaging techniques
total resection

Software Mentioned

Brainlab Smartbrush Suite

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.